Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2021

View Archived Issues

MK2 is a therapeutic target in PDAC that mediates resistance to FIRINOX chemotherapy

Targeting cyclophilin A potentiates chemotherapeutic efficacy in chemoresistant colorectal cancer

YES1 seen to induce the growth of TNBC

Kallyope patents AMPK activators

G1 Therapeutics discloses new CDK2 inhibitors

Senda Biosciences presents AhR antagonists for cancer

Aligos Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Sinocelltech describes method for enhancing immunogenicitiy of Fc-fusion antigen

Tweaking KLF4 enhances cellular reprogramming

Targeting LIF/LIFR axis as potential therapeutic strategy against adiposity-driven TNBC

HLA-DRB1 copy number predicts response to immunosuppressive therapy in acquired aplastic anemia

One-step synthetic approach for the fabrication of oriented antibody-decorated MOF nanocrystals

Nucleoside analogue sangivamycin shows in vitro activity against several variants of SARS-CoV-2

Discovery of long-acting entecavir prodrugs

BridGene and Peter MacCallum Cancer Centre enter research collaboration for ovarian cancer

GALE is a biomarker of inherited thrombocytopenia

SAB-185 neutralizes SARS-CoV-2 Omicron variant in in vitro pseudovirus model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...